Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Comments Open On Symbols In Device Labeling

Executive Summary

US FDA is reopening the comment period on a rule that allows medical device manufacturers to use standardized symbols on product labeling. The docket will be open through May 20.

You may also be interested in...

FDA Finalizes Device Symbol-In-Labeling Rule Retaining Glossary Requirement

Industry complaints that a 2013 FDA proposal calling for a glossary explanation for standalone symbols used in device labels went beyond internationally harmonized standards did not persuade the agency to drop the glossary from its June 14 final rule, but FDA does provide more flexibility on symbols that can be employed in device labeling.

COVID-19 Serology Templates: FDA Updates Sponsor Template, Adds Home Test Document

The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.

Hologic Aptima Assay Cleared For HIV Detection

Already cleared to monitor the viral load in HIV-positive individuals, the test has now been approved for initial diagnosis as well.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts